Gujarat Kidney And Superspeciality Limited has initiated a remote e-voting process to seek shareholder approval for the variation in the utilization of its Initial Public Offering (IPO) proceeds. The resolution, classified as a Special Resolution, proposes to reallocate unutilized funds amounting to Rs 37.76 crore. The e-voting facility is open from 9 a.m. on Friday, June 05, 2026, to 5 p.m. on Saturday, July 04, 2026.

The company filed the Postal Ballot Notice with BSE Limited and the National Stock Exchange of India Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was published in The Financial Express (English, Ahmedabad edition) and Gujarat Mitra (Gujarati, Vadodara Edition). The communication was signed by Pragnesh Bharpoda, Managing Director, on June 4, 2026.

Proposed Variation in Objects

The Board proposes to modify the objects of the IPO proceeds to enhance infrastructure and facilities in its subsidiary, Raj Palmland Hospital Private Limited, and the parent company. Specifically, the company plans to utilize Rs 6.12 crore from the healthcare expansion object for investing in new infrastructure on lease, installing equipment, and creating an IVF facility. The remaining balance of Rs 19.02 crore from this object will be transferred to the object for funding inorganic growth through unidentified acquisitions and general corporate purposes, increasing the total allocation for that head to Rs 31.64 crore.

The company stated that the first variation approved by shareholders on April 25, 2026, involved incorporating a wholly-owned subsidiary in Bharuch. However, realizing it already has two subsidiaries there, the Board decided to avoid duplication of efforts and investment. Instead, it will enhance the infrastructure of Raj Palmland Hospital Private Limited and develop an IVF facility in the parent company, Gujarat Kidney Super Speciality Hospital at Vadodara. The Board will be authorized to finalize vendors and investment terms.

Utilization Status

The following table details the utilization of IPO proceeds as of May 29, 2026:

E-Voting and Scrutiny Details

Members of the company whose names appear in the Register of Members as of the Cut-off Date, Friday, May 29, 2026, are eligible to vote. The company has engaged MUFG Intime India Private Limited as the Registrar and Transfer Agents to facilitate the remote e-voting process. M/s SPANJ & Associates, Practicing Company Secretaries, has been appointed as the Scrutinizer to ensure the process is conducted fairly. The results will be announced on or before July 07, 2026.

Gujarat Kidney And Superspeciality Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026, on May 28, 2026. The board approved the results based on the recommendations of the Audit Committee, confirming that the auditor's reports are unmodified. The company also appointed internal and secretarial auditors and deferred the appointment of a Chief Executive Officer.

Financial Performance

For the full year ended March 31, 2026, the company reported a standalone profit after tax of ₹990.14 lacs, compared to ₹910.90 lacs in the previous year. Total standalone income rose to ₹4,059.47 lacs from ₹3,528.11 lacs in FY25. On a consolidated basis, profit after tax increased to ₹1,681.18 lacs from ₹949.94 lacs, with total income reaching ₹8,288.60 lacs.

The board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The statutory auditor, M/s Y M Shah & Co., issued an unmodified report on the annual financial results and conducted a limited review of the quarterly results.

Key Appointments

The board appointed Mr Siddharth Atulbhai Shah as the Internal Auditor for FY 2026-27. Additionally, SPANJ & Associates was appointed as the Secretarial Auditor for a period of five consecutive years from 2026-27 to 2030-31, subject to shareholder approval at the ensuing Annual General Meeting.

Corporate Actions

The company will conduct a postal ballot to seek shareholder approval for a variation in the objects of its Initial Public Offering (IPO) via special resolution. The agenda for the appointment of a Chief Executive Officer was deferred by the board.